Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
INmune Bio Inc
INMB | US
1.18
USD-0.10
-7.81%
INMB | US
About INmune Bio Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
1.18
Open
1.27
High
1.29
Low
1.16
INmune Bio Inc. a clinical-stage immunology company focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies solid tumors and chronic inflammation. The company's development programs include INKmune which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4 a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor Inc.; Immune Ventures LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton Florida.
View LessINMB | US
Risk
77.9
Sharpe
-0.88
Luna's Score
31/100
Recommendation
Sell
Luna says (INMB | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
76.1%1 month
77.9%3 months
71.5%6 months
70.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.67
Debt to equity
0.15
Debt to assets
0.10
Ent. to EBITDA
-5.31
Ent. to rev.
864.92
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
23.40M
MarketCap(USD)
23.40M
Div. yield
-
Op. margin
-44.46K
Erngs. growth
-
Rev. growth
-63.20
Ret. on equity
-86.04
Short ratio
8.29
Short perc.
17.48
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.23
Range1M
0.38
Range3M
0.71
Volumes: Market Activity
Rel. volume
0.97
Price X volume
528.59K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.31 | - | Cheaper |
| Ent. to Revenue | 864.92 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.67 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 71.54 | - | Par |
| Debt to Equity | 0.15 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 23.40M | - | Emerging |
